I
Innovita Biological Technology Co Ltd
SSE:688253
Innovita Biological Technology Co Ltd
SSE:688253
Price:
36.49
CNY
1.28%
Market Closed
Market Cap:
¥5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
I
|
Innovita Biological Technology Co Ltd
SSE:688253
|
CN |
Income Statement
Earnings Waterfall
Innovita Biological Technology Co Ltd
Innovita Biological Technology Co Ltd
Income Statement
Innovita Biological Technology Co Ltd
Innovita Biological Technology Co Ltd
Currency: CNY
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
327
N/A
|
267
-18%
|
360
+34%
|
373
+4%
|
447
+20%
|
512
+15%
|
420
-18%
|
415
-1%
|
478
+15%
|
625
+31%
|
676
+8%
|
720
+7%
|
621
-14%
|
547
-12%
|
477
-13%
|
431
-10%
|
|
| Gross Profit | |||||||||||||||||
| Cost of Revenue |
(77)
|
(76)
|
(122)
|
(136)
|
(174)
|
(205)
|
(157)
|
(144)
|
(141)
|
(119)
|
(131)
|
(139)
|
(128)
|
(118)
|
(106)
|
(102)
|
|
| Gross Profit |
250
N/A
|
192
-23%
|
237
+24%
|
237
0%
|
273
+15%
|
307
+13%
|
264
-14%
|
271
+3%
|
338
+25%
|
506
+50%
|
544
+8%
|
581
+7%
|
494
-15%
|
429
-13%
|
371
-13%
|
329
-11%
|
|
| Operating Income | |||||||||||||||||
| Operating Expenses |
(104)
|
(94)
|
(107)
|
(120)
|
(161)
|
(169)
|
(176)
|
(174)
|
(152)
|
(235)
|
(232)
|
(236)
|
(257)
|
(252)
|
(230)
|
(226)
|
|
| Selling, General & Administrative |
(79)
|
(80)
|
(78)
|
(84)
|
(98)
|
(101)
|
(102)
|
(101)
|
(99)
|
(133)
|
(137)
|
(138)
|
(154)
|
(139)
|
(134)
|
(126)
|
|
| Research & Development |
(28)
|
(35)
|
(48)
|
(56)
|
(68)
|
(71)
|
(61)
|
(58)
|
(49)
|
(65)
|
(75)
|
(80)
|
(92)
|
(110)
|
(95)
|
(97)
|
|
| Depreciation & Amortization |
(10)
|
(3)
|
0
|
0
|
(12)
|
0
|
0
|
0
|
(12)
|
0
|
0
|
0
|
(14)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
13
|
24
|
19
|
21
|
18
|
4
|
(13)
|
(16)
|
8
|
(37)
|
(20)
|
(18)
|
2
|
(3)
|
(2)
|
(3)
|
|
| Operating Income |
145
N/A
|
98
-32%
|
130
+33%
|
117
-10%
|
112
-5%
|
138
+24%
|
87
-37%
|
96
+10%
|
185
+93%
|
271
+46%
|
313
+15%
|
346
+11%
|
237
-31%
|
177
-25%
|
141
-20%
|
103
-26%
|
|
| Pre-Tax Income | |||||||||||||||||
| Interest Income Expense |
(5)
|
(10)
|
22
|
45
|
57
|
62
|
48
|
30
|
34
|
40
|
36
|
36
|
39
|
38
|
37
|
36
|
|
| Non-Reccuring Items |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(20)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Total Other Income |
(2)
|
(1)
|
(3)
|
(3)
|
(4)
|
(3)
|
(3)
|
(3)
|
(2)
|
(2)
|
(0)
|
(0)
|
0
|
0
|
0
|
1
|
|
| Pre-Tax Income |
138
N/A
|
87
-37%
|
149
+71%
|
159
+7%
|
165
+3%
|
197
+20%
|
133
-33%
|
123
-7%
|
198
+61%
|
309
+56%
|
349
+13%
|
381
+9%
|
277
-27%
|
215
-22%
|
178
-17%
|
140
-21%
|
|
| Net Income | |||||||||||||||||
| Tax Provision |
(18)
|
(9)
|
(15)
|
(16)
|
(14)
|
(19)
|
(14)
|
(14)
|
(24)
|
(43)
|
(46)
|
(49)
|
(30)
|
(19)
|
(13)
|
(7)
|
|
| Income from Continuing Operations |
120
|
78
|
133
|
143
|
151
|
178
|
120
|
110
|
174
|
266
|
303
|
332
|
247
|
196
|
166
|
133
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
120
N/A
|
78
-36%
|
133
+72%
|
143
+7%
|
151
+5%
|
178
+18%
|
120
-33%
|
110
-8%
|
174
+59%
|
266
+53%
|
303
+14%
|
332
+10%
|
247
-26%
|
196
-21%
|
166
-16%
|
133
-19%
|
|
| EPS (Diluted) |
0.88
N/A
|
0.56
-36%
|
0.97
+73%
|
1.04
+7%
|
1.24
+19%
|
1.3
+5%
|
0.87
-33%
|
0.8
-8%
|
1.28
+60%
|
1.95
+52%
|
2.22
+14%
|
2.43
+9%
|
1.81
-26%
|
1.43
-21%
|
1.21
-15%
|
0.98
-19%
|
|
Switch to:
Switch to:
See Also
Discover More
